MYGN
MYRIAD GENETICS INC
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$4.21
+5.78%Year over year
Reported trailing growth
- Revenue
- -3.2%
- EBITDA
- +87.4%
- EBIT
- +76.4%
- EPS
- +72.1%
- Free cash flow
- +81.7%
- Operating cash flow
- +134.1%
Forward estimates
Based on analyst estimates
- Revenue
- +0.2%
- EBITDA
- +114.4%
- EPS
- +48.0%
Three-year CAGR
- Revenue
- +6.7%
- EBITDA
- —
- EBIT
- +23.0%
- Net income
- —
- EPS
- —
- Free cash flow
- +33.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026